Nan, Zhejiang, and Shannxi), 2 municipalities (Beijing and Shanghai), and 3 autonomous regions (Ningxia, Guangxi and Tibet) in mainland China. Of the 21 studies, 11 were conducted at the provincial level and 10 were at the city level. With regard to the age of subjects, 8, 3, and 16 studies were based on individuals aged 15 years or above, 16 years or above, and 18 years or above, respectively. The CIDI was adopted in 11 studies, and the SCID was used in 10 studies. Table 1 and Supplementary Table 1 (Table S1) showed the get AZD3759 characteristics of these studies. All studies received an assessment score of at least 7. Specifically, studies obtained a score of 10 (n = 10), 9 (n = 5), 8 (n = 4) and 7 (n = 2). More details of the assessment of study quality are provided in Table S2. Selection of a fixed-effects or random-effects model.In this study, the Necrosulfonamide cancer current and lifetime prevalence of ADs and their subtypes in the overall population, by gender (males, females), and by location (urban, rural) were all estimated with a random-effects model. Both the fixed- and random-effects models were used in to identify gender or location differences; the results are presented in detail in Table 2.Prevalence of ADs and their subtypes. Anxiety disorders. Overall prevalence. The lifetime prevalence of ADs was 41.12 (95 CI: 31.09?1.15) (Fig. 2), while the current prevalence was 24.47 (95 CI: 17.97?0.98) (Fig. 3). Figure 4 shows that no significant trend was detected in the temporal trend of the lifetime prevalence of ADs from 2001 to 2012. Varying prevalences of ADs were observed in different Chinese provinces, among which Ningxia had the highest current and lifetime prevalences and Guangxi had the lowest. The colorcoded map in Fig. 5 illustrates the different degrees of the lifetime prevalence of ADs. This map was divided into four sections according to prevalence, from highest to lowest. However, the majority of the map zones indicated that these corresponding regions lacked available epidemiological data on ADs. Thus, no distribution difference could be detected in the color-coded map of mainland China.Prevalence by gender. The current and lifetime prevalences of ADs were 15.37 (95 CI: 8.31?2.43) and 28.46 (95 CI: 8.63?8.29), respectively, for males and 25.74 (95 CI: 11.87?9.61) and 53.69 (95 CI: 16.74 ?90.65), respectively, for females (Table 2). Compared with females, males had a lower risk of developing Ads, with ORs of 0.57 (95 CI: 0.44?.75) for current prevalence and 0.56 (95 CI: 0.43?.73) for lifetime prevalence (Table 2). Prevalence by location. Urban (current: 16.99, 95 CI: 3.40?0.58; lifetime: 37.97, 95 CI: 10.97?4.97) and rural (current: 17.68, 95 CI: 6.84?8.51; lifetime: 36.83, 95 CI: -0.32?3.99) locations had a similar prevalence of Ads (Table 2). No significant difference was found between urban and rural location, with ORs of 1.18 (95 CI: 0.76?.84) for current prevalence and of 0.97 (95 CI: 0.62?.51) for lifetime prevalence (Table 2). Generalized anxiety disorder. Overall prevalence. The current and lifetime prevalence of GAD was 5.17 (95 CI: 3.72?.63) (Fig. 3) and 4.66 (95 CI: 3.17?.14), respectively (Fig. 2). Prevalence by gender. The prevalence of GAD in males (current: 2.97, 95 CI: 1.83?.12; lifetime: 0.43, 95 CI: 0.13?.72) was lower than that in females (current: 6.32, 95 CI: 3.45?.19; lifetime: 5.63, 95 CI: 2.59?.66) (Table 2), indicating that males were less likely to suffer from GAD than females (OR, current: 0.44, 95.Nan, Zhejiang, and Shannxi), 2 municipalities (Beijing and Shanghai), and 3 autonomous regions (Ningxia, Guangxi and Tibet) in mainland China. Of the 21 studies, 11 were conducted at the provincial level and 10 were at the city level. With regard to the age of subjects, 8, 3, and 16 studies were based on individuals aged 15 years or above, 16 years or above, and 18 years or above, respectively. The CIDI was adopted in 11 studies, and the SCID was used in 10 studies. Table 1 and Supplementary Table 1 (Table S1) showed the characteristics of these studies. All studies received an assessment score of at least 7. Specifically, studies obtained a score of 10 (n = 10), 9 (n = 5), 8 (n = 4) and 7 (n = 2). More details of the assessment of study quality are provided in Table S2. Selection of a fixed-effects or random-effects model.In this study, the current and lifetime prevalence of ADs and their subtypes in the overall population, by gender (males, females), and by location (urban, rural) were all estimated with a random-effects model. Both the fixed- and random-effects models were used in to identify gender or location differences; the results are presented in detail in Table 2.Prevalence of ADs and their subtypes. Anxiety disorders. Overall prevalence. The lifetime prevalence of ADs was 41.12 (95 CI: 31.09?1.15) (Fig. 2), while the current prevalence was 24.47 (95 CI: 17.97?0.98) (Fig. 3). Figure 4 shows that no significant trend was detected in the temporal trend of the lifetime prevalence of ADs from 2001 to 2012. Varying prevalences of ADs were observed in different Chinese provinces, among which Ningxia had the highest current and lifetime prevalences and Guangxi had the lowest. The colorcoded map in Fig. 5 illustrates the different degrees of the lifetime prevalence of ADs. This map was divided into four sections according to prevalence, from highest to lowest. However, the majority of the map zones indicated that these corresponding regions lacked available epidemiological data on ADs. Thus, no distribution difference could be detected in the color-coded map of mainland China.Prevalence by gender. The current and lifetime prevalences of ADs were 15.37 (95 CI: 8.31?2.43) and 28.46 (95 CI: 8.63?8.29), respectively, for males and 25.74 (95 CI: 11.87?9.61) and 53.69 (95 CI: 16.74 ?90.65), respectively, for females (Table 2). Compared with females, males had a lower risk of developing Ads, with ORs of 0.57 (95 CI: 0.44?.75) for current prevalence and 0.56 (95 CI: 0.43?.73) for lifetime prevalence (Table 2). Prevalence by location. Urban (current: 16.99, 95 CI: 3.40?0.58; lifetime: 37.97, 95 CI: 10.97?4.97) and rural (current: 17.68, 95 CI: 6.84?8.51; lifetime: 36.83, 95 CI: -0.32?3.99) locations had a similar prevalence of Ads (Table 2). No significant difference was found between urban and rural location, with ORs of 1.18 (95 CI: 0.76?.84) for current prevalence and of 0.97 (95 CI: 0.62?.51) for lifetime prevalence (Table 2). Generalized anxiety disorder. Overall prevalence. The current and lifetime prevalence of GAD was 5.17 (95 CI: 3.72?.63) (Fig. 3) and 4.66 (95 CI: 3.17?.14), respectively (Fig. 2). Prevalence by gender. The prevalence of GAD in males (current: 2.97, 95 CI: 1.83?.12; lifetime: 0.43, 95 CI: 0.13?.72) was lower than that in females (current: 6.32, 95 CI: 3.45?.19; lifetime: 5.63, 95 CI: 2.59?.66) (Table 2), indicating that males were less likely to suffer from GAD than females (OR, current: 0.44, 95.
Heme Oxygenase heme-oxygenase.com
Just another WordPress site
